Developer docs
API playgroundTry for free, no card

Search company profiles

Mindpeak

Full company profile

uuid00005nn

Namestring
Mindpeak
Legal namestring
Mindpeak GmbH
Websiteurl
mindpeak.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mindpeak GmbH is a Hamburg, Germany-based developer of AI-powered digital pathology software for cancer detection, quantification, and classification. Founded in 2018, the company operates a platform-plus-modules architecture centered on its proprietary peakFrontier foundational AI model, which analyzes whole-slide images across H&E, immunohistochemistry (IHC), and multiplex immunofluorescence (mIF) modalities and converts tissue information into structured, quantitative outputs. The portfolio includes BioPharma-facing modules (peakDiscover for biomarker discovery, peakPredict for therapy response prediction, peakDeploy for multi-site trial deployment, peakAcademy for pathologist training) and diagnostic lab modules (peakDx, peakDissect, PhenoScout AI) organized into clinical suites for breast, PD-L1, and HER2 scoring. Mindpeak holds 11 CE-IVD certified products, ISO 13485:2016 QMS certification, and a granted patent across 17 EU member states and the UK.

Mindpeak generates revenue through three streams: AI software licensing (CE-IVD certified and RUO algorithms sold to diagnostic labs on a subscription/recurring basis), clinical trial services (biomarker analysis and companion diagnostic support for pharma), and partner integration revenue via reseller/distribution agreements with Leica Biosystems, Epredia, and Pathomation. The company serves two primary customer segments: BioPharma companies (AstraZeneca, Discovery Life Sciences, Tubulis) needing biomarker analysis for drug development and clinical trial endpoints, and diagnostic laboratories and healthcare systems (Unilabs, Intermountain Health, Charité Berlin, PathGroup, Bio Reference Labs) seeking reproducible AI-assisted cancer diagnosis. Named validation includes multi-center studies with AstraZeneca across 12 academic centers and 1,000+ breast cancer cases.

The company has scaled rapidly: its AI has supported over 50,000 patient diagnoses across 40+ labs in 20+ countries as of late 2025, up from 30,000+ diagnoses at the September 2024 Series A. The $15.3 million Series A round (September 2024) led by ZEISS Ventures and InnoVentureFund is funding US expansion via the August 2025 launch of Mindpeak Inc. in Cambridge, MA, alongside high-profile channel partnerships with Leica Biosystems (global reseller, March 2026) and Epredia (EU distributor, February 2026).

Short descriptiontext

Mindpeak GmbH develops AI-powered digital pathology software for cancer detection, quantification, and classification across H&E, IHC, and mIF tissue images. It sells CE-IVD certified algorithms, biomarker analysis, and clinical trial services to BioPharma companies and diagnostic laboratories globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHamburg, Germany
HQ citystring
Hamburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology AI, cancer diagnostic software, biomarker analysis tools, medical imaging AI, clinical decision support
Industry5 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Prepackaged Software7372
  • Laboratory Analytical Instruments3826
Product category
Digital Pathology AI Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI Software Licensing
TypeSubscription Recurring
Description

Mindpeak licenses its CE-IVD certified AI algorithms and diagnostic software to diagnostic laboratories and healthcare providers. Products are available as both research use only (RUO) and CE-IVD certified diagnostic tools, suggesting a mix of perpetual licensing and subscription models.

mindpeak.ai
2Clinical Trial Services
TypeProfessional Services
Description

Mindpeak provides biomarker analysis and companion diagnostic services to pharmaceutical companies for clinical trials, supporting patient stratification and endpoint evaluation.

mindpeak.ai
3Partner Integration Revenue
TypeLicensing Royalties
Description

Revenue generated through reseller and distribution agreements with partners like Leica Biosystems, Epredia, and Pathomation who resell Mindpeak's AI solutions.

mindpeak.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1peakFrontier
Description

Foundational AI architecture that analyses digital pathology images including multiplex immunofluorescence, immunohistochemistry and H&E, converting complex tissue information into structured, quantitative outputs for regulated clinical and research use.

mindpeak.ai
+8 more records
Core offering1 text field

Mindpeak develops and licenses AI-based diagnostic software for the detection, quantification, and classification of cancer in digital pathology tissue images. The company sells CE-IVD certified algorithms and research-use-only tools to pharmaceutical companies (for biomarker discovery and clinical trial support) and diagnostic laboratories (for routine cancer diagnostics in breast, lung, prostate, and gastrointestinal pathology). Products are sold under the peakFrontier platform with specialized applications including peakDiscover, peakPredict, peakDeploy, peakAcademy, peakDx, peakDissect, and PhenoScout AI.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mindpeak is an AI-powered digital pathology company offering a platform-plus-modules architecture. The core technology is peakFrontier, a foundational AI architecture that analyzes digital pathology images (H&E, IHC, mIF) and powers specialized applications. For BioPharma, the platform includes peakDiscover (biomarker discovery), peakPredict (predictive analytics), peakDeploy (scalable deployment), peakAcademy (training), and Phenoscout AI (multiplex immunofluorescence analysis). For Diagnostic Labs, offerings include peakDx and peakDissect decision support tools, organized into diagnostic suites: Breast Suite (HER2, ER/PR), PD-L1 Suite, and HER2 Suite. The company holds 11 CE-IVD certified products and operates under ISO 13485 QMS. Mindpeak's AI supports over 40 labs globally with 18+ IMS integrations, and has enabled diagnosis for over 50,000 patients.

Product and service13 records
1peakFrontier AI Platform
CategoryCore AI Platform
Description

Foundational AI architecture that analyzes digital pathology whole-slide images including H&E, immunohistochemistry, and multiplex immunofluorescence, converting complex tissue information into structured, quantitative outputs for regulated clinical and research use. Powers the entire portfolio of specialized applications.

2peakDiscover
CategoryBiopharma AI Solution
Description

Extracts tissue and cellular features to characterize the tumor microenvironment and identify biomarker signatures for biomarker discovery and pharmaceutical drug development.

3peakPredict
CategoryBiopharma AI Solution
Description

Predictive AI ecosystem that analyzes tissue-based features in relation to treatment response and clinical outcomes, enabling patient stratification for targeted therapies from standard H&E images.

4peakDeploy
CategoryBiopharma AI Solution
Description

Enables scalable deployment of AI tissue biomarker solutions across laboratory networks, supporting reproducible analysis in multi-site clinical trials and routine diagnostics.

5peakAcademy
CategoryBiopharma AI Solution
Description

AI-native training platform supporting standardized, reproducible biomarker assessment and pathologist training programs for consistent diagnostic results across sites.

6peakDx (Breast Suite, PD-L1 Suite, HER2 Suite)
CategoryClinical Diagnostic AI
Description

CE-IVD certified diagnostic AI suite for clinical pathology including Breast Suite (HER2, ER/PR, invasive breast cancer detection), PD-L1 Suite (pan-tumor PD-L1 quantification), and HER2 Suite (including HER2-low and HER2-ultralow detection) with algorithms for breast, lung, and gastrointestinal cancer diagnostics.

7peakDissect
CategoryClinical Diagnostic AI
Description

Automated macrodissection solution using Pan-Tumor AI to ensure optimal tissue selection for genomic sequencing while preserving limited patient samples.

8PhenoScout AI
CategoryMultiplex Immunofluorescence AI
Description

Next-generation multiplex immunofluorescence analysis solution that automates phenotype identification, biomarker quantification, and spatial readouts to reduce variability and support large-scale translational studies for pharma, diagnostics, and academic research.

9Ki-67 AI
CategoryBiomarker AI Module
Description

Automated Ki-67 proliferation index scoring solution supporting both hotspot-scoring and global-scoring methods according to IKWG guidelines for cancer prognosis and treatment planning.

10ER/PR AI
CategoryBiomarker AI Module
Description

Automated estrogen receptor (ER) and progesterone receptor (PR) scoring for breast cancer diagnostics and treatment selection.

11p53 AI
CategoryBiomarker AI Module
Description

Automated p53 biomarker quantification for cancer diagnostics, available through the Leica Biosystems Aperio integration under the global reseller agreement.

12Mindpeak Intelligence Platform (BioPharma Services)
CategoryBioPharma Services Platform
Description

End-to-end clinical and research services platform combining Mindpeak's AI solutions for biomarker discovery, clinical trial support, go-to-market preparation, and biomarker training for pharmaceutical partners.

13Prostate Cancer AI Solution
CategoryClinical Diagnostic AI
Description

AI solution for prostate cancer detection and diagnostics, expanding Mindpeak's diagnostic portfolio beyond breast, lung, and gastrointestinal pathology.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Co-exhibit partnership at AACR 2026 to showcase integrated multiplex immunofluorescence workflow combining Revolune's mIF reagents with Mindpeak's AI-powered pathology image analysis software (PhenoScout). Aims to simplify spatial biology workflows for biomarker discovery and cancer research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Strategic partnership to integrate AI-powered digital pathology for biomarker analysis in global clinical trials. Collaboration combines Mindpeak's AI platform with Discovery's tissue biomarker services, including their Biomarker Academy that has trained over 6,000 pathologists and supported more than 2,000 clinical trial programs.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-19
Description

Global reseller agreement announced March 2026. Leica Biosystems, a Danaher company and global leader in digital pathology, resells Mindpeak's AI applications within its Aperio digital pathology ecosystem. Initial offering includes nine AI applications for biomarker quantification covering Ki-67, HER2, ER/PR, p53, and PD-L1.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-24
Description

EU distribution agreement for Mindpeak's AI-powered image recognition software in cancer diagnostics. Epredia, a subsidiary of PHC Holdings Corporation, integrates Mindpeak's technology for pixel-level analysis of digital tissue images for breast, lung, and gastrointestinal pathology diagnostics.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Collaborative agreement to explore opportunities at the intersection of biotechnology and AI-driven diagnostics. Tubulis develops next-generation antibody-drug conjugates (ADCs) and Mindpeak provides AI for biomarker characterization.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Partnership with one of the leading providers of anatomic, clinical, molecular and digital pathology services in the US. Combines Mindpeak's AI image analysis technology with PathGroup's pathologist-led network to bring AI into everyday diagnostics.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-19
Description

Strategic collaboration for native integration of Mindpeak's CE-IVD certified AI algorithms (Ki-67, HER2, zero-click PD-L1) into Pathomation's digital pathology platform. Pathomation's worldwide presence spans Europe, Asia, and Latin America.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-01
Description

Mindpeak joined Techcyte's Fusion Partner Program to integrate its explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-19
Description

Multi-center observational study in Brazil, Egypt, and Kenya evaluating AI-powered pathology tools for breast cancer diagnosis. Collaboration also includes multinational study validating AI-assisted HER2 IHC scoring across 12 academic centers and 1,000+ breast cancer cases presented at ASCO 2025 and ESMO 2025.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-19
Description

Observational study in Brazil, Egypt, and Kenya evaluating AI-powered digital pathology risk assessment tools for breast cancer diagnosis to validate AI software effectiveness in resource-limited regions.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-12-13
Description

Partnership to develop integrated Multiplex Immunofluorescence (mIF) solution combining ZEISS's advanced instruments with Mindpeak's AI-powered pathology analysis. Joint solution integrates both companies' offerings for enhanced value in the mIF market.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Collaborative study assessing the efficacy of Mindpeak's Onychomycosis AI algorithm for automated detection of hyphae from multiple slides.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based AI pathology company developing diagnostic and biomarker algorithms for pharma and clinical labs. Closely comparable to Mindpeak across BioPharma CDx services, IHC/H&E AI, and lab deployment, though operating at significantly larger scale and funding.

TypeDirect peer
Description

Israel-based AI pathology company with CE-marked cancer diagnostic algorithms deployed across health systems. Direct overlap with Mindpeak's peakDx breast/prostate/PD-L1 suite and clinical lab GTM.

TypeDirect peer
Description

US AI pathology company with FDA-authorized products and foundation model focus for oncology diagnostics. Direct competitor across clinical lab deployment and pharma biomarker partnerships.

4Aignostics
TypeDirect peer
Description

Berlin-based AI pathology spin-out from Charité focusing on multi-modal biomarker discovery and pharma services. Highly comparable on BioPharma GTM, foundation-model technology, and EU origin story.

TypeDirect peer
Description

France-based AI company deploying pathology foundation models for pharma and diagnostics. Comparable on multi-modal AI, BioPharma CDx focus, and EU regulatory positioning.

TypeDirect peer
Description

US digital pathology platform company that distributes third-party AI algorithms alongside its Concentriq platform. Comparable as both a potential partner and competitor to Mindpeak in lab workflows.

TypeEmerging player
Description

South Korea-based AI medical imaging company with pathology and mammography products including CE-marked and FDA-cleared diagnostics. Comparable on cancer diagnostic AI focus and clinical lab sales motion.

TypeEmerging player
Description

Israel-based spatial biology AI company serving pharma with tissue-based biomarker analytics. Highly comparable to Mindpeak's PhenoScout AI and peakDiscover for pharma R&D use cases.

TypeBroad incumbent
Description

Roche's diagnostics arm offers its own AI image analysis alongside the Ventana DP platform, competing and partnering across the same lab workflows Mindpeak serves.

TypeBroad incumbent
Description

Philips offers IntelliSite Pathology Solution with companion AI algorithms, and Christiaan Neeleman's prior role illustrates the overlap with Mindpeak's lab deployment ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mindpeak

Digital Pathology AI Softwaremindpeak.ai

Mindpeak GmbH develops AI-powered digital pathology software for cancer detection, quantification, and classification across H&E, IHC, and mIF tissue images. It sells CE-IVD certified algorithms, biomarker analysis, and clinical trial services to BioPharma companies and diagnostic laboratories globally.

What Mindpeak does

Mindpeak GmbH is a Hamburg, Germany-based developer of AI-powered digital pathology software for cancer detection, quantification, and classification. Founded in 2018, the company operates a platform-plus-modules architecture centered on its proprietary peakFrontier foundational AI model, which analyzes whole-slide images across H&E, immunohistochemistry (IHC), and multiplex immunofluorescence (mIF) modalities and converts tissue information into structured, quantitative outputs. The portfolio includes BioPharma-facing modules (peakDiscover for biomarker discovery, peakPredict for therapy response prediction, peakDeploy for multi-site trial deployment, peakAcademy for pathologist training) and diagnostic lab modules (peakDx, peakDissect, PhenoScout AI) organized into clinical suites for breast, PD-L1, and HER2 scoring. Mindpeak holds 11 CE-IVD certified products, ISO 13485:2016 QMS certification, and a granted patent across 17 EU member states and the UK.

Mindpeak generates revenue through three streams: AI software licensing (CE-IVD certified and RUO algorithms sold to diagnostic labs on a subscription/recurring basis), clinical trial services (biomarker analysis and companion diagnostic support for pharma), and partner integration revenue via reseller/distribution agreements with Leica Biosystems, Epredia, and Pathomation. The company serves two primary customer segments: BioPharma companies (AstraZeneca, Discovery Life Sciences, Tubulis) needing biomarker analysis for drug development and clinical trial endpoints, and diagnostic laboratories and healthcare systems (Unilabs, Intermountain Health, Charité Berlin, PathGroup, Bio Reference Labs) seeking reproducible AI-assisted cancer diagnosis. Named validation includes multi-center studies with AstraZeneca across 12 academic centers and 1,000+ breast cancer cases.

The company has scaled rapidly: its AI has supported over 50,000 patient diagnoses across 40+ labs in 20+ countries as of late 2025, up from 30,000+ diagnoses at the September 2024 Series A. The $15.3 million Series A round (September 2024) led by ZEISS Ventures and InnoVentureFund is funding US expansion via the August 2025 launch of Mindpeak Inc. in Cambridge, MA, alongside high-profile channel partnerships with Leica Biosystems (global reseller, March 2026) and Epredia (EU distributor, February 2026).

Mindpeak firmographics

Firmographics
Name
Mindpeak
Legal name
Mindpeak GmbH
Website
https://mindpeak.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Mindpeak GmbH develops AI-powered digital pathology software for cancer detection, quantification, and classification across H&E, IHC, and mIF tissue images. It sells CE-IVD certified algorithms, biomarker analysis, and clinical trial services to BioPharma companies and diagnostic laboratories globally.
Ownership category
akta.pro rank

Mindpeak industry classification

Industry
Product category
Digital Pathology AI Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Digital pathology AI
  • Cancer diagnostic software
  • Biomarker analysis tools
  • Medical imaging AI
  • Clinical decision support

Where Mindpeak is headquartered

Location

Headquarters

HQ city
Hamburg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Mindpeak business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Software Licensing: Mindpeak licenses its CE-IVD certified AI algorithms and diagnostic software to diagnostic laboratories and healthcare providers. Products are available as both research use only (RUO) and CE-IVD certified diagnostic tools, suggesting a mix of perpetual licensing and subscription models.
  2. Clinical Trial Services: Mindpeak provides biomarker analysis and companion diagnostic services to pharmaceutical companies for clinical trials, supporting patient stratification and endpoint evaluation.
  3. Partner Integration Revenue: Revenue generated through reseller and distribution agreements with partners like Leica Biosystems, Epredia, and Pathomation who resell Mindpeak's AI solutions.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Mindpeak product offering

Product offering

Core offering

Mindpeak develops and licenses AI-based diagnostic software for the detection, quantification, and classification of cancer in digital pathology tissue images. The company sells CE-IVD certified algorithms and research-use-only tools to pharmaceutical companies (for biomarker discovery and clinical trial support) and diagnostic laboratories (for routine cancer diagnostics in breast, lung, prostate, and gastrointestinal pathology). Products are sold under the peakFrontier platform with specialized applications including peakDiscover, peakPredict, peakDeploy, peakAcademy, peakDx, peakDissect, and PhenoScout AI.

Product overview

Mindpeak is an AI-powered digital pathology company offering a platform-plus-modules architecture. The core technology is peakFrontier, a foundational AI architecture that analyzes digital pathology images (H&E, IHC, mIF) and powers specialized applications. For BioPharma, the platform includes peakDiscover (biomarker discovery), peakPredict (predictive analytics), peakDeploy (scalable deployment), peakAcademy (training), and Phenoscout AI (multiplex immunofluorescence analysis). For Diagnostic Labs, offerings include peakDx and peakDissect decision support tools, organized into diagnostic suites: Breast Suite (HER2, ER/PR), PD-L1 Suite, and HER2 Suite. The company holds 11 CE-IVD certified products and operates under ISO 13485 QMS. Mindpeak's AI supports over 40 labs globally with 18+ IMS integrations, and has enabled diagnosis for over 50,000 patients.

Differentiator

Problem solved

Functional benefit

Brands

  • peakFrontier: Foundational AI architecture that analyses digital pathology images including multiplex immunofluorescence, immunohistochemistry and H&E, converting complex tissue information into structured, quantitative outputs for regulated clinical and research use.
  • PhenoScout AI
  • peakDiscover
  • peakPredict
  • peakDeploy
  • peakAcademy
  • peakDx
  • peakDissect
  • Phenoscout AI

Products and services

  • peakFrontier AI Platform Foundational AI architecture that analyzes digital pathology whole-slide images including H&E, immunohistochemistry, and multiplex immunofluorescence, converting complex tissue information into structured, quantitative outputs for regulated clinical and research use. Powers the entire portfolio of specialized applications.
  • peakDiscover Extracts tissue and cellular features to characterize the tumor microenvironment and identify biomarker signatures for biomarker discovery and pharmaceutical drug development.
  • peakPredict Predictive AI ecosystem that analyzes tissue-based features in relation to treatment response and clinical outcomes, enabling patient stratification for targeted therapies from standard H&E images.
  • peakDeploy Enables scalable deployment of AI tissue biomarker solutions across laboratory networks, supporting reproducible analysis in multi-site clinical trials and routine diagnostics.
  • peakAcademy AI-native training platform supporting standardized, reproducible biomarker assessment and pathologist training programs for consistent diagnostic results across sites.
  • peakDx (Breast Suite, PD-L1 Suite, HER2 Suite) CE-IVD certified diagnostic AI suite for clinical pathology including Breast Suite (HER2, ER/PR, invasive breast cancer detection), PD-L1 Suite (pan-tumor PD-L1 quantification), and HER2 Suite (including HER2-low and HER2-ultralow detection) with algorithms for breast, lung, and gastrointestinal cancer diagnostics.
  • peakDissect Automated macrodissection solution using Pan-Tumor AI to ensure optimal tissue selection for genomic sequencing while preserving limited patient samples.
  • PhenoScout AI Next-generation multiplex immunofluorescence analysis solution that automates phenotype identification, biomarker quantification, and spatial readouts to reduce variability and support large-scale translational studies for pharma, diagnostics, and academic research.
  • Ki-67 AI Automated Ki-67 proliferation index scoring solution supporting both hotspot-scoring and global-scoring methods according to IKWG guidelines for cancer prognosis and treatment planning.
  • ER/PR AI Automated estrogen receptor (ER) and progesterone receptor (PR) scoring for breast cancer diagnostics and treatment selection.
  • p53 AI Automated p53 biomarker quantification for cancer diagnostics, available through the Leica Biosystems Aperio integration under the global reseller agreement.
  • Mindpeak Intelligence Platform (BioPharma Services) End-to-end clinical and research services platform combining Mindpeak's AI solutions for biomarker discovery, clinical trial support, go-to-market preparation, and biomarker training for pharmaceutical partners.
  • Prostate Cancer AI Solution AI solution for prostate cancer detection and diagnostics, expanding Mindpeak's diagnostic portfolio beyond breast, lung, and gastrointestinal pathology.

Companies that use Mindpeak

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Mindpeak technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature9 records

Mindpeak partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

  • Revolune GmbHcoreStrategic or Co-development Partner · 16 April 2026Co-exhibit partnership at AACR 2026 to showcase integrated multiplex immunofluorescence workflow combining Revolune's mIF reagents with Mindpeak's AI-powered pathology image analysis software (PhenoScout). Aims to simplify spatial biology workflows for biomarker discovery and cancer research.
  • Discovery Life SciencesmajorStrategic or Co-development Partner · 24 March 2026Strategic partnership to integrate AI-powered digital pathology for biomarker analysis in global clinical trials. Collaboration combines Mindpeak's AI platform with Discovery's tissue biomarker services, including their Biomarker Academy that has trained over 6,000 pathologists and supported more than 2,000 clinical trial programs.
  • Leica BiosystemsmajorChannel Partner/ Reseller/ Distributor · 19 March 2026Global reseller agreement announced March 2026. Leica Biosystems, a Danaher company and global leader in digital pathology, resells Mindpeak's AI applications within its Aperio digital pathology ecosystem. Initial offering includes nine AI applications for biomarker quantification covering Ki-67, HER2, ER/PR, p53, and PD-L1.
  • EprediacoreChannel Partner/ Reseller/ Distributor · 24 February 2026EU distribution agreement for Mindpeak's AI-powered image recognition software in cancer diagnostics. Epredia, a subsidiary of PHC Holdings Corporation, integrates Mindpeak's technology for pixel-level analysis of digital tissue images for breast, lung, and gastrointestinal pathology diagnostics.
  • TubulisminorStrategic or Co-development Partner · 1 December 2025Collaborative agreement to explore opportunities at the intersection of biotechnology and AI-driven diagnostics. Tubulis develops next-generation antibody-drug conjugates (ADCs) and Mindpeak provides AI for biomarker characterization.
  • PathGroupmajorStrategic or Co-development Partner · 11 November 2025Partnership with one of the leading providers of anatomic, clinical, molecular and digital pathology services in the US. Combines Mindpeak's AI image analysis technology with PathGroup's pathologist-led network to bring AI into everyday diagnostics.
  • PathomationcoreTechnology or Integration · 19 August 2025Strategic collaboration for native integration of Mindpeak's CE-IVD certified AI algorithms (Ki-67, HER2, zero-click PD-L1) into Pathomation's digital pathology platform. Pathomation's worldwide presence spans Europe, Asia, and Latin America.
  • Techcyte Inc.coreTechnology or Integration · 1 July 2025Mindpeak joined Techcyte's Fusion Partner Program to integrate its explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics.
  • AstraZenecamajorStrategic or Co-development Partner · 19 March 2025Multi-center observational study in Brazil, Egypt, and Kenya evaluating AI-powered pathology tools for breast cancer diagnosis. Collaboration also includes multinational study validating AI-assisted HER2 IHC scoring across 12 academic centers and 1,000+ breast cancer cases presented at ASCO 2025 and ESMO 2025.
  • AstraZenecamajorStrategic or Co-development Partner · 19 March 2025Observational study in Brazil, Egypt, and Kenya evaluating AI-powered digital pathology risk assessment tools for breast cancer diagnosis to validate AI software effectiveness in resource-limited regions.
  • ZEISS MicroscopymajorStrategic or Co-development Partner · 13 December 2024Partnership to develop integrated Multiplex Immunofluorescence (mIF) solution combining ZEISS's advanced instruments with Mindpeak's AI-powered pathology analysis. Joint solution integrates both companies' offerings for enhanced value in the mIF market.
  • Sagis DiagnosticsminorStrategic or Co-development Partner · 4 November 2024Collaborative study assessing the efficacy of Mindpeak's Onychomycosis AI algorithm for automated detection of hyphae from multiple slides.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Mindpeak competitors and assessment

Company assessment

Direct peers

  • PathAI: Boston-based AI pathology company developing diagnostic and biomarker algorithms for pharma and clinical labs. Closely comparable to Mindpeak across BioPharma CDx services, IHC/H&E AI, and lab deployment, though operating at significantly larger scale and funding.
  • Ibex Medical Analytics: Israel-based AI pathology company with CE-marked cancer diagnostic algorithms deployed across health systems. Direct overlap with Mindpeak's peakDx breast/prostate/PD-L1 suite and clinical lab GTM.
  • Paige: US AI pathology company with FDA-authorized products and foundation model focus for oncology diagnostics. Direct competitor across clinical lab deployment and pharma biomarker partnerships.
  • Aignostics: Berlin-based AI pathology spin-out from Charité focusing on multi-modal biomarker discovery and pharma services. Highly comparable on BioPharma GTM, foundation-model technology, and EU origin story.
  • Owkin: France-based AI company deploying pathology foundation models for pharma and diagnostics. Comparable on multi-modal AI, BioPharma CDx focus, and EU regulatory positioning.
  • Proscia: US digital pathology platform company that distributes third-party AI algorithms alongside its Concentriq platform. Comparable as both a potential partner and competitor to Mindpeak in lab workflows.

Emerging players

  • Lunit: South Korea-based AI medical imaging company with pathology and mammography products including CE-marked and FDA-cleared diagnostics. Comparable on cancer diagnostic AI focus and clinical lab sales motion.
  • Nucleai: Israel-based spatial biology AI company serving pharma with tissue-based biomarker analytics. Highly comparable to Mindpeak's PhenoScout AI and peakDiscover for pharma R&D use cases.

Broad incumbents

  • Roche (Ventana Digital Pathology): Roche's diagnostics arm offers its own AI image analysis alongside the Ventana DP platform, competing and partnering across the same lab workflows Mindpeak serves.
  • Philips (Digital Pathology): Philips offers IntelliSite Pathology Solution with companion AI algorithms, and Christiaan Neeleman's prior role illustrates the overlap with Mindpeak's lab deployment ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Mindpeak social profiles

Digital presence

Mindpeak compliance and trust

Trust signal

Compliance3 records

Mindpeak financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mindpeak leadership team

Management profile

Number of profiles

Profiles7 records

Mindpeak subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mindpeak funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mindpeak M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mindpeak

What does Mindpeak do?

Mindpeak develops and licenses AI-based diagnostic software for the detection, quantification, and classification of cancer in digital pathology tissue images. The company sells CE-IVD certified algorithms and research-use-only tools to pharmaceutical companies (for biomarker discovery and clinical trial support) and diagnostic laboratories (for routine cancer diagnostics in breast, lung, prostate, and gastrointestinal pathology). Products are sold under the peakFrontier platform with specialized applications including peakDiscover, peakPredict, peakDeploy, peakAcademy, peakDx, peakDissect, and PhenoScout AI.

Is Mindpeak a public or private company?

Mindpeak is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mindpeak founded?

Mindpeak was founded in 2018. It employs 11 to 50 people.

Where is Mindpeak based?

Mindpeak is headquartered in Hamburg, Germany, in the Europe region.

How does Mindpeak make money?

Three revenue lines are on record. AI Software Licensing is the primary driver. The others are clinical Trial Services and partner Integration Revenue.

Who are Mindpeak's main competitors?

Direct peers on record are PathAI, Ibex Medical Analytics, Paige, Aignostics, Owkin and Proscia. Emerging players are Lunit and Nucleai. Broad incumbents are Roche (Ventana Digital Pathology) and Philips (Digital Pathology).

Does Mindpeak have an API?

No public API is recorded for Mindpeak.

What industry is Mindpeak in?

Mindpeak's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMindpeak and Revolune Announce Commercial Co-Selling Partnership to Deliver End-to-End Spatial Biology SolutionsMindpeak and Revolune announced a commercial co-selling partnership to offer an integrated workflow combining multiplex tissue staining with AI-powered image analysis. The partnership pairs Revolune's multiplex IF kits with Mindpeak's PhenoScout AI platform, providing researchers with a streamlined path from staining to spatial insights. An introductory launch promotion offers promotional PhenoScout AI analysis credits to researchers purchasing qualifying kits.EIN PresswireBeyond the Algorithm: What Does It Take to Make AI Work in Everyday Pathology?Mindpeak announced at ECP 2026 that six of its AI algorithms are available through Leica Biosystems' Aperio AI Store, launching within the Aperio HALO AP software environment. The integration aims to reduce workflow steps and improve interoperability, with validation and deployment considerations emphasized.openPR.comSegmentation, Major Trends, and Competitive Overview of the Explainable Artificial Intelligence for Diagnostics MarketThe global explainable artificial intelligence for diagnostics market is projected to reach $5.28 billion by 2030, growing at a compound annual growth rate of 25.6%, driven by stricter regulatory requirements for transparent AI models and increasing demand from clinicians for interpretable diagnostic outputs. In July 2025, Germany-based Mindpeak GmbH partnered with US-based Techcyte Inc. to integrate Mindpeak's explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics. Additionally, US-based Evident Vascular Inc. launched an AI-powered intravascular ultrasound system in October 2023 to enhance imaging quality for vascular disease detection.PR NewswireRevolune y MindPeak presentarán su flujo de trabajo integrado de inmunofluorescencia multiplex en la AACR 2026Revolune GmbH and MindPeak announced they will present a joint integrated multiplex immunofluorescence (mIF) workflow at the AACR 2026 Annual Meeting, combining Revolune's mIF reagents with MindPeak's AI-powered pathology image analysis solutions. The collaboration aims to simplify complex spatial biology workflows, enabling researchers to generate high-quality multiplex tissue data and extract biological insights more efficiently. Visitors can view the combined workflow at booth 1660 at the AACR 2026 conference.PR NewswireÀ l'occasion d'AACR 2026, Revolune et MindPeak présentent un flux de travail intégré d'immunofluorescence multiplexeRevolune GmbH and MindPeak are presenting a joint integrated multiplex immunofluorescence (mIF) workflow at the AACR 2026 annual meeting, combining Revolune's mIF reagents with MindPeak's AI-powered image analysis to streamline spatial biology research for cancer and biomarker discovery. The partnership aims to reduce the technical complexity that has hindered broader adoption of multiplex workflows in tissue analysis, from staining through quantitative interpretation. Visitors to AACR 2026 can learn more about the combined solution at stand 1660.PR NewswireRevolune and MindPeak to Showcase Integrated Multiplex Immunofluorescence Workflow at AACR 2026Revolune GmbH and MindPeak announced they will exhibit together at the AACR Annual Meeting 2026 to showcase an integrated spatial biology workflow combining Revolune's multiplex immunofluorescence reagents with MindPeak's AI-powered pathology image analysis software. The partnership aims to simplify the technically complex and difficult-to-scale multiplex immunofluorescence workflows commonly used in tumor biology research and biomarker discovery. Both companies seek to reduce adoption barriers for spatial biology workflows by offering an integrated solution from tissue staining to data analysis.PR NewswireRevolune und MindPeak präsentieren auf der AACR 2026 einen integrierten Workflow für die Multiplex-ImmunfluoreszenzRevolune GmbH and MindPeak announced they will co-exhibit at the AACR 2026 annual meeting, presenting an integrated workflow that combines Revolune's multiplex immunofluorescence reagents with MindPeak's AI-powered image analysis solutions for spatial biology research. The partnership aims to simplify complex spatial biology workflows by offering researchers a more integrated and user-friendly process from staining to analysis. Both companies expect this collaboration to help reduce barriers to adopting spatial biology workflows and accelerate translational cancer research and biomarker discovery.